

Garry G Graham

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5077617/garry-g-graham-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

2,753
citations

25
h-index

52
g-index

63
ext. papers

3,105
ext. citations

4.8
avg, IF

4.73
L-index

#	Paper	IF	Citations
55	Serum concentrations of estriol vary widely after application of vaginal oestriol cream. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2354-2360	3.8	
54	Limitations of drug concentrations used in cell culture studies for understanding clinical responses of NSAIDs. <i>Inflammopharmacology</i> , 2021 , 29, 1261-1278	5.1	2
53	A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2486-2496	3.8	2
52	The safety and pharmacokinetics of metformin in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 565-575	6.1	6
51	Determination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1126-1127, 121764	3.2	5
50	Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance. <i>Therapeutic Advances in Psychopharmacology</i> , 2019 , 9, 2045125319836889	4.9	
49	Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2772-2783	3.8	5
48	A Multicentre Open-Label Pharmacokinetic-Pharmacodynamic Study of Febuxostat in Patients with Chronic Gout. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO1-11-12	0	
47	Comment on Massive metformin overdose by Chiew et al. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2938-2939	3.8	2
46	Could metformin be used in patients with advanced chronic kidney disease?. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 302-303	6.7	0
45	Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 459-475	6.2	20
44	Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration. <i>American Journal of Kidney Diseases</i> , 2016 , 68, 990-992	7.4	10
43	Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1363-6	2.4	29
42	Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2157-64	2.4	132
41	The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 617-23	3.8	6
40	The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. <i>Inflammopharmacology</i> , 2013 , 21, 201-32	5.1	319
39	Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 373-84	6.2	84

38	The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis. <i>Drug Safety</i> , 2013 , 36, 733-46	5.1	54
37	Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 932-8	3.8	26
36	Salicylates 2013 , 1-6		
35	Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. <i>Arthritis Research and Therapy</i> , 2012 , 14, R189	5.7	27
34	Clinical pharmacokinetics of metformin. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 81-98	6.2	690
33	A bifunctional role for group IIA secreted phospholipase A2 in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolism. <i>Journal of Biological Chemistry</i> , 2011 , 286, 2492-503	5.4	26
32	FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?. <i>Inflammopharmacology</i> , 2010 , 18, 47-55	5.1	17
31	Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrations. <i>Biochemical Pharmacology</i> , 2010 , 79, 1156-64	6	53
30	A risk-benefit assessment of paracetamol (acetaminophen) combined with caffeine. <i>Pain Medicine</i> , 2010 , 11, 951-65	2.8	24
29	Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 623-44	6.2	117
28	Tolerability of paracetamol. <i>Drug Safety</i> , 2005 , 28, 227-40	5.1	94
27	Mechanism of action of paracetamol. <i>American Journal of Therapeutics</i> , 2005 , 12, 46-55	1	384
26	Paracetamol should be first-line therapy in osteoarthritis. <i>Medical Journal of Australia</i> , 2005 , 182, 198-9; author reply 199	4	2
25	Mechanisms of action of paracetamol and related analgesics. <i>Inflammopharmacology</i> , 2003 , 11, 401-13	5.1	56
24	Tolerability of Paracetamol*. <i>Drugs</i> , 2003 , 63, 39-42	12.1	6
23	Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). <i>Current Pharmaceutical Design</i> , 2002 , 8, 1063-75	3.3	38
22	Inhibition of prostaglandin synthesis in intact cells by paracetamol (acetaminophen). <i>Inflammopharmacology</i> , 2001 , 9, 131-142	5.1	12
21	Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1674-9	5.9	39

20	Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. <i>Clinical Pharmacokinetics</i> , 1999 , 36, 191-210	6.2	59
19	The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes. III. The formation of aurocyanide by myeloperoxidase. <i>Biochemical Pharmacology</i> , 1998 , 56, 307-12	6	26
18	Measurement of total phospholipids in urine of patients treated with gentamicin. <i>British Journal of Clinical Pharmacology</i> , 1997 , 43, 435-40	3.8	9
17	Reactions of the Antiarthritic Drug Aurothiomalate With Phenylmercury(II) Compounds: NMR Studies. <i>Metal-Based Drugs</i> , 1996 , 3, 269-76		
16	Pharmacokinetic analysis of the time course of effect of atracurium. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 57, 390-7	6.1	4
15	The cellular metabolism and effects of gold complexes. <i>Metal-Based Drugs</i> , 1994 , 1, 395-404		20
14	The kinetics of effect of neuromuscular blocking drugs. <i>Keio Journal of Medicine</i> , 1994 , 43, 27-30	1.6	1
13	Stress in mice increases intrinsic pentobarbitone sensitivity by a predominantly pharmacodynamic mechanism. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1991 , 18, 703-10	3	2
12	Stereoselective disposition of ibuprofen and flurbiprofen in rats. <i>Chirality</i> , 1990 , 2, 134-40	2.1	50
11	The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes--I. The effects of aurocyanide on the oxidative burst of polymorphonuclear leukocytes. <i>Biochemical Pharmacology</i> , 1990 , 39, 1687-95	6	27
10	The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes--II. Evidence for the formation and biological activity of aurocyanide. <i>Biochemical Pharmacology</i> , 1990 , 39, 1697-702	6	29
9	Stereoselective disposition of ibuprofen enantiomers in synovial fluid. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 43, 480-7	6.1	56
8	Variability in response to NSAIDs. Fact or fiction?. <i>Drugs</i> , 1988 , 36, 643-51	12.1	47
7	Pharmacokinetics and metabolism of non-steroidal anti-inflammatory drugs. <i>Medical Journal of Australia</i> , 1987 , 147, 597-602	4	19
6	¹ H, ¹³ C NMR, and electronic absorption spectroscopic studies of the interaction of cyanide with aurothiomalate. <i>Journal of Inorganic Biochemistry</i> , 1985 , 25, 163-73	4.2	40
5	Disposition of and clinical response to salicylates in patients with rheumatoid disease. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 35, 585-93	6.1	12
4	Salicylate metabolite kinetics after several salicylates. <i>Clinical Pharmacology and Therapeutics</i> , 1981 , 30, 266-75	6.1	32
3	Chlorbutol toxicity and dependence. <i>Medical Journal of Australia</i> , 1979 , 1, 288	4	6

2	Multiple drug interactions with phenytoin. <i>Medical Journal of Australia</i> , 1977 , 2, 467-8	4	2
1	Effects of tricyclic antidepressants on drug metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1975 , 18, 191-9	6.1	21